AR and cancer: We next tested both degraders in the androgen-resistantprostate cancer cell line 22Rv1 that expresses wild-type AR and AR-V7and demonstrated that both JP-2-217 and JP-2-224, but not VPC-14228or a previously reported VHL-based AR-V7 PROTAC (compound 6),40 degraded both wild-type AR and AR-V7 (Figures 5h and S11e–h).